PET reveals patient responses to new Alzheimer’s disease drug
AuntMinnie
OCTOBER 27, 2023
Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Food and Drug Administration, with a decision expected by the end of 2023. Donanemab is currently under review for approval by the U.S.
Let's personalize your content